Did Neurocept receive any enforcement letters, warning letters, or subpoena notices from FDA or EMA in 2024?

1. What I searched and what the sources show

I reviewed FDA quarterly FAERS potential-signal postings for 2024 (January–March, April–June, July–September, October–December) and the FDA’s 2024 warning-letter page for health fraud; none of those documents in the supplied results reference Neurocept receiving an enforcement, warning, or subpoena notice in 2024 ^{[1] [2] [5] [6] [3]}. The supplied EMA items are high-level yearly and meeting summaries about authorisations, CHMP opinions and 2024 agency activity and do not mention enforcement actions against Neurocept ^{[4] [7]}.

2. FDA enforcement materials available in the results — what they typically include

The FDA FAERS “potential signals” reports list drugs that appeared in adverse-event reporting reviews for particular quarters, a surveillance tool rather than an enforcement action; presence on FAERS-signal lists does not equal an FDA enforcement letter ^{[1] [2] [5] [6]}. Separately, the FDA’s 2024 warning-letters page groups health-fraud-related warning letters but the supplied excerpt is an index example and does not show Neurocept being named ^[3].

3. EMA materials in the results — scope and limitations for enforcement searches

The EMA documents in the set are annual summaries and CHMP meeting highlights focused on approvals, recommendations and monitoring of authorised medicines; they explain EMA’s ongoing safety surveillance role but the excerpts do not include enforcement letters or subpoenas tied to specific companies such as Neurocept ^{[4] [7]}. These types of EMA pages are not comprehensive logs of company-specific enforcement actions.

4. What these sources can’t tell us (important limitation)

Available sources do not mention Neurocept receiving any FDA or EMA enforcement letters, warning letters, or subpoenas in 2024; however, absence from the supplied set is not definitive proof that no action occurred because (a) company-specific enforcement notices might appear in other FDA/EMA pages, press releases, or third‑party reports not included here, and (b) some enforcement communications (for example, investigational subpoenas or internal correspondence) are not publicly posted immediately or at all in the documents supplied (not found in current reporting) ^{[3] [4]}.

5. How regulators typically publish enforcement actions — context for your evaluation

When FDA issues public warning letters they appear on agency pages and are often cross‑reported by trade press; FAERS quarterly summaries flag potential safety signals but are distinct from enforcement communications ^{[3] [1]}. EMA public communications focus on CHMP opinions, recommendations and pharmacovigilance summaries; the agency also posts some regulatory decisions, but company‑specific enforcement notices can be distributed via different EMA channels or national competent authorities ^{[4] [7]}.

6. Practical next steps if you need confirmation beyond these sources

To be certain, check: (a) FDA Warning Letters search by company name on the FDA website (the provided page is an index) and the FDA news/press release archive; (b) the EMA public database and CHMP meeting minutes or press releases for enforcement notices; and (c) Neurocept’s own SEC filings or press releases, which commonly disclose material regulatory contacts — none of which are in the supplied results, so I cannot cite them here (not found in current reporting) ^{[3] [4]}.

7. Alternative viewpoints and transparency about gaps

Some trade outlets in the supplied set summarize many regulatory actions across companies and sectors but do not single out Neurocept; those summaries can create a sense that regulators were active in 2024 without proving action against any particular firm ^{[8] [9]}. Because the search results here are broad and not company‑specific, they leave open the possibility that Neurocept could have been the subject of private or later‑published notices not captured in this dataset (not found in current reporting) ^{[8] [9]}.

If you want, I can: (a) run a fresh, company‑name–focused search through FDA warning‑letter lists, FDA press releases, EMA enforcement communications, and Neurocept’s public filings and press releases (if you provide those sources or allow broader web queries); or (b) prepare exact search queries and locations to check so you—or I in a follow‑up with expanded sources—can confirm definitively.